Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2020; 17(7):921-930. doi:10.7150/ijms.43789 This issue Cite

Research Paper

Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database

Satoshi Nakao1, Shiori Hasegawa1,2, Kazuyo Shimada1, Ririka Mukai1, Mizuki Tanaka1, Kiyoka Matsumoto1, Hiroaki Uranishi4, Mayuko Masuta5, Hiroaki Ikesue2, Tohru Hashida2, Kazuhiro Iguchi3, Mitsuhiro Nakamura1✉

1. Laboratory of Drug Informatics, Gifu Pharmaceutical University; Gifu, Japan.
2. Department of pharmacy, Kobe City Medical Center General Hospital; Kobe, Japan.
3. Laboratory of Community Pharmacy, Gifu Pharmaceutical University; Gifu, Japan.
4. Current address: Division of Pharmacy, Nara Medical University Hospital, 840, Shijocho, Kashihara-shi, Nara, 634-8522, Japan.
5. Current address: Division of Pharmacy, Kyoto City Hospital, 1-2, Mibu Higashitakadacho, Nakagyo-ku Kyoto-shi, Kyoto, 604-8845, Japan.

✉ Corresponding author: Mitsuhiro Nakamura, Ph.D. Professor, Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4, Daigaku-Nishi, Gifu, 501-1196, JAPAN, Tel: +81-58-230-8100, Fax: +81-58-230-8105, E-mail: mnakamuraac.jp.

Citation:
Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci 2020; 17(7):921-930. doi:10.7150/ijms.43789. https://www.medsci.org/v17p0921.htm
Other styles

File import instruction

Abstract

Clostridium difficile-associated colitis (CDAC) may cause gastrointestinal illness, ranging in severity from mild diarrhea to fulminant colitis and even mortality. The purpose of this study was to evaluate anti-infective-related CDAC profiles using the Japanese Adverse Drug Event Report (JADER) database.

Methods: We selected case reports of adverse events of CDAC as specified in the Medical Dictionary for Regulatory Activities. The association between the number of administered anti-infectives and aging was evaluated using reporting odds ratio (ROR) and adjusted for covariates using multiple-logistic regression. We also evaluated anti-infective-related CDAC-onset profiles using Weibull shape parameter.

Results: The JADER database contained 534 688 reports from April 2004 to June 2018. There were 1222 anti-infective related CDAC events. The top five anti-infectives were as follows: third-generation cephalosporins (Anatomical Therapeutic Chemical (ATC) code: J01DD, 313 cases), fluoroquinolones (ATC code: J01MA, 201 cases), macrolides (ATC code: J01FA, 146 cases), carbapenems (ATC code: J01DH, 143 cases), and penicillins with extended spectrum (ATC code: J01CA, 103 cases). The adjusted RORs (95% confidence interval) in individuals using 1, 2, and ≥ 3 anti-infectives were 8.88 (7.05-11.18), 9.77 (6.89-13.86), and 18.39 (11.85-28.54), respectively. Moreover, 47.2% of CDACs occurred within 7 days of anti-infective therapy initiation. The adjusted ROR of interaction terms of ≥ 70 years × 1 drug was 21.81 (14.56-32.68).

Conclusion: Our results suggest that the number of administered anti-infectives and patient age are associated with CDAC. These data may be particularly beneficial to prescribers and would contribute to improving the management of CDAC.

Keywords: Clostridium difficile-associated colitis, anti-infective, adverse event, JADER

Citation styles

APA
Nakao, S., Hasegawa, S., Shimada, K., Mukai, R., Tanaka, M., Matsumoto, K., Uranishi, H., Masuta, M., Ikesue, H., Hashida, T., Iguchi, K., Nakamura, M. (2020). Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. International Journal of Medical Sciences, 17(7), 921-930. https://doi.org/10.7150/ijms.43789.

ACS
Nakao, S.; Hasegawa, S.; Shimada, K.; Mukai, R.; Tanaka, M.; Matsumoto, K.; Uranishi, H.; Masuta, M.; Ikesue, H.; Hashida, T.; Iguchi, K.; Nakamura, M. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int. J. Med. Sci. 2020, 17 (7), 921-930. DOI: 10.7150/ijms.43789.

NLM
Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci 2020; 17(7):921-930. doi:10.7150/ijms.43789. https://www.medsci.org/v17p0921.htm

CSE
Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M. 2020. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci. 17(7):921-930.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use